MA
Maze Therapeutics, Inc.
MAZE · NASDAQ
$22.52 -3.84% (-$0.90)
1M -23.92%
Market Cap $1.25B
P/E Ratio -
Div. Yield -
ROE 34.94%
Piotroski F-Score Weak
3/9Valuation
36 /100
Fair P/B 2.75x
P/S 62.32x
EV/EBITDA N/A
Growth
100 /100
Growing Book val. growth 51.82%
Rev. growth N/A
FCF growth N/A
Profitability
20 /100
Weak Net margin 667.95%
Op. margin 728.06%
FCF margin 534.20%
Quality
0 /100
Poor ROE 34.94%
ROA 25.13%
Asset turnover 0.04x
Debt
69 /100
Low Current ratio 18.31x
Int. coverage -73.34x
Debt/Equity 0.13x
Stability
1 /100
Unstable EPS volatility 2,355.06%
Profitable years 0
Beta 2.16x
Bulios Scoring popisuje kvalitu a minulost firmy, ne budoucí výnos. Vysoké skóre není nákupní signál. Zjistit více
Zeptejte se StockBota na MAZE
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Jason Coloma
Employees
141
Headquarters
South San Francisco
Nadcházející události
05 LIS
Earnings
Upcoming earnings report